Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Diabetologia 41, 271278
The key is understanding what to expect, managing your diet appropriately, and having clinical support in place throughout your treatment
The newer dual-action agent tirzepatide (Mounjaro) targets both GLP-1 and GIP receptors and is licensed in the UK for type 2 diabetes management
Stay hydrated Tirzepatide can cause dehydration through reduced food intake and gastrointestinal side effects
doi: 10.1042/CS20110006 66 PathakNMPathakVGaultVAMcCleanSIrwinNFlattPR
FDA-approved uses of tirzepatide (Mounjaro and Zepbound): Mounjaro is an FDA-approved dual receptor agonist used to treat blood sugar levels in individuals with type 2 diabetes mellitus
US$ 20.03
US$ 23.13
US$ 27.87
US$ 26.03
US$ 23.50
US$ 21.32
US$ 20.50
